secwatch.observer — SEC 8-K summary
======================================

Issuer:     EKSO BIONICS HOLDINGS, INC. (CHRN)
CIK:        0001549084
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001437749-25-000928
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ekso Bionics expects record Q4 2024 revenue of $5.0-$5.1M, preliminary
----------------------------------------------------------------------

- Q4 2024 revenue estimated at $5.0-5.1M (company record vs $4.8M in Q4 2023).
- Cash $6.5M at Dec 31, 2024, down from $8.6M a year earlier.
- Net cash used in ops Q4 2024 estimated $1.5M, improving from $1.6M year ago.
- CEO highlights initial CMS reimbursement for Ekso Indego Personal device.
- Full Q4 and FY 2024 results expected in first week of March 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549084/000143774925000928/0001437749-25-000928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549084/000143774925000928/ekso20250108_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-000928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer